Jennison Associates LLC Has $120.95 Million Position in Natera, Inc. (NASDAQ:NTRA)

Jennison Associates LLC lessened its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 1.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 764,056 shares of the medical research company’s stock after selling 7,906 shares during the period. Jennison Associates LLC owned 0.58% of Natera worth $120,950,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Blue Trust Inc. increased its holdings in Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 97 shares during the last quarter. Versant Capital Management Inc grew its position in shares of Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after buying an additional 166 shares during the period. Quarry LP raised its position in shares of Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 190 shares during the period. Covestor Ltd boosted its stake in Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after acquiring an additional 95 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in Natera by 32.7% during the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 106 shares during the period. Institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on NTRA. Canaccord Genuity Group increased their target price on shares of Natera from $165.00 to $180.00 and gave the stock a “buy” rating in a report on Friday, January 3rd. Piper Sandler lifted their target price on Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a report on Monday, November 18th. Robert W. Baird increased their price target on Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Sanford C. Bernstein raised their price target on Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, January 10th. Finally, StockNews.com lowered Natera from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $165.88.

Natera Trading Down 0.2 %

Shares of Natera stock opened at $176.56 on Tuesday. The stock has a market cap of $23.31 billion, a P/E ratio of -100.32 and a beta of 1.66. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 12-month low of $66.68 and a 12-month high of $183.00. The business’s 50 day moving average is $167.14 and its 200-day moving average is $139.03.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.31. The firm had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company’s quarterly revenue was up 63.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.95) earnings per share. Equities research analysts predict that Natera, Inc. will post -1.56 earnings per share for the current fiscal year.

Insider Activity

In other Natera news, CEO Steven Leonard Chapman sold 4,728 shares of the company’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $146.41, for a total value of $692,226.48. Following the transaction, the chief executive officer now directly owns 185,034 shares in the company, valued at $27,090,827.94. The trade was a 2.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Roelof Botha sold 87,473 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $169.12, for a total transaction of $14,793,433.76. Following the sale, the director now owns 1,224,787 shares of the company’s stock, valued at approximately $207,135,977.44. This represents a 6.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 268,229 shares of company stock valued at $44,521,025 over the last three months. Insiders own 7.60% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.